Sarcoma metastatic – Diagnostics – Overview of Information and Clinical Research

When sarcoma spreads beyond its original location to distant parts of the body, it becomes metastatic sarcoma, a situation that requires specialized diagnostic approaches to guide treatment decisions and monitor disease progression.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing symptoms that might suggest sarcoma should seek medical evaluation. The most common warning sign is a lump that can be felt through the skin, which may or may not cause pain. Other concerning symptoms include unexplained bone pain, a bone breaking without clear cause, belly pain, or unexplained weight loss. These symptoms warrant a visit to a healthcare professional who can determine whether further testing is necessary.^[1]

For metastatic soft tissue sarcoma, diagnostics become especially important when the cancer has already been treated once and there is concern about recurrence. Around 25% of metastatic soft tissue sarcoma cases occur after initial treatment for the primary tumor, meaning the cancer returns even after surgery, chemotherapy, or radiation. In some situations, doctors may detect metastatic disease at the very first diagnosis, before even finding the original tumor location. This happens because cancer cells can break away from the primary site and travel through the bloodstream or lymphatic system to settle in distant organs.^[2]

People who have already been diagnosed with localized sarcoma should remain vigilant during follow-up care. Regular monitoring is essential because sarcomas have a remarkable tendency to spread to specific organs, particularly the lungs. According to medical literature, approximately 83% of metastatic soft tissue sarcoma occurs in the lungs, though the cancer can also spread to the liver, bones, subcutaneous tissue, and lymph nodes.^[2]^[4]

The timing of diagnostic testing matters greatly. Early detection of metastatic disease can open up more treatment options and potentially improve outcomes. Patients who notice any new or worsening symptoms after completing initial sarcoma treatment should not hesitate to contact their healthcare team. Similarly, anyone with risk factors for sarcoma, such as previous radiation exposure, certain inherited genetic conditions, or long-term swelling in the arms or legs, should discuss appropriate screening timelines with their doctor.^[3]

Diagnostic Methods for Identifying Metastatic Sarcoma

The diagnostic journey for metastatic soft tissue sarcoma typically begins with a thorough physical examination. During this evaluation, a healthcare professional asks about symptoms and medical history, looking for clues that might indicate the presence or spread of cancer. The physical exam helps the doctor understand the nature of any lumps, their location, size, and whether they cause discomfort. This initial assessment guides decisions about which additional tests will be most helpful.^[22]

Biopsy Procedures

A biopsy is the cornerstone of diagnosing metastatic soft tissue sarcoma. This procedure involves removing a sample of tissue so it can be examined under a microscope in a laboratory. There are several types of biopsies, and the choice depends on where the suspected tumor is located and how accessible it is.^[2]

A core biopsy is often preferred because it tends to be more accurate than other methods. This technique uses a wide needle to remove multiple tissue samples. Doctors may use imaging tests like ultrasound to guide the needle to exactly the right spot, ensuring they collect tissue from the tumor itself rather than surrounding healthy tissue. This precision is crucial because the characteristics of the tissue sample will determine the diagnosis and treatment plan.^[2]

An incisional biopsy is another option that removes either a portion of a lump or a complete tissue sample for laboratory analysis. Sometimes surgeons perform a biopsy during the operation to remove the cancer, allowing immediate examination of the tissue. This approach can help guide surgical decisions in real-time.^[2]

⚠️ Important

The way a biopsy is performed matters significantly for sarcoma diagnosis. The biopsy site and technique must be carefully planned because poorly placed biopsies can complicate later surgical treatment. Patients should ensure their biopsy is performed by specialists experienced in sarcoma care, as this can affect the success of subsequent treatments.

Laboratory Testing of Tissue Samples

Once tissue samples are collected, laboratory tests provide detailed information that helps doctors understand exactly what type of sarcoma is present and how aggressive it might be. These tests examine several important features of the cancer cells, including their appearance and number, the presence of certain genes and proteins, changes in chromosomes, and specific markers called antigens. Antigens are substances that can trigger immune responses and help identify the specific type of cancer.^[2]

This level of detailed analysis is essential because there are over 100 different subtypes of sarcoma, each potentially requiring different treatment approaches. The laboratory findings help doctors determine not only the diagnosis but also the grade of the tumor, which indicates how quickly it is likely to grow and spread.^[5]

Imaging Tests to Detect Spread

After confirming the diagnosis through biopsy, doctors use various imaging techniques to determine whether and where the cancer has spread. These tests create detailed pictures of the inside of the body, allowing doctors to see tumors that cannot be felt during a physical exam.^[22]

A chest X-ray is often one of the first imaging tests ordered because the lungs are the most common site for sarcoma to spread. X-rays use radiation to create images and can reveal abnormal masses or nodules in the lungs that might indicate metastatic disease.^[2]

CT scans, also called computed tomography scans, provide more detailed three-dimensional images than standard X-rays. A CT machine rotates around the patient, taking multiple images from different angles. A computer then combines these images to create cross-sectional views of bones, blood vessels, and soft tissues. CT scans are particularly valuable for detecting small metastases and assessing the exact size and location of tumors.^[2]

MRI scans, or magnetic resonance imaging scans, use magnets and radio waves instead of radiation to create detailed pictures of soft tissues inside the body. MRI is especially useful for examining muscles, tendons, and other connective tissues where sarcomas originate. These scans can show whether tumors have grown into nearby structures like nerves or blood vessels, information that is critical for planning surgery.^[2]

A PET scan, which stands for positron emission tomography, works differently from other imaging tests. Before the scan, patients receive an injection of a special radioactive substance that cancer cells tend to absorb. The PET scanner then detects this substance, creating images that highlight areas where cancer cells are actively growing. PET scans are particularly helpful for identifying cancerous tumor cells throughout the entire body and can sometimes detect metastases that other imaging methods miss.^[2]

In some cases, doctors may recommend a bone scan to check whether sarcoma has spread to the skeleton. This test involves injecting a small amount of radioactive material that travels through the bloodstream and collects in bones where cancer may be present.^[22]

Blood Tests

Blood tests play a supporting role in the diagnostic process. A complete blood count measures the numbers of different types of blood cells, which can be affected by cancer or its treatment. Blood chemistry tests evaluate how well organs like the kidneys and liver are functioning, information that becomes important when planning treatment.^[2]

While blood tests alone cannot diagnose metastatic sarcoma, they provide valuable context about a patient’s overall health and help doctors monitor for complications during treatment. The combination of biopsy results and comprehensive imaging, along with blood test findings, allows the medical team to stage the cancer accurately and develop an appropriate treatment plan.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of existing treatments to find better ways to help patients with metastatic sarcoma. Participating in a clinical trial can give patients access to promising new therapies that are not yet widely available. However, before someone can join a clinical trial, they must undergo specific diagnostic tests to confirm they meet the study’s requirements.^[4]

The diagnostic criteria for clinical trial enrollment typically follow the same standard methods used for general diagnosis, but with additional specifications. Researchers need to ensure that all participants have similar characteristics so they can accurately measure how well the experimental treatment works. This means diagnostic tests must not only confirm the presence of metastatic sarcoma but also provide detailed information about the specific subtype, stage, and other tumor characteristics.^[2]

Biopsy Requirements for Trials

Clinical trials often require a fresh biopsy, even if a patient had one performed previously. This is because researchers need recently collected tissue to perform specific molecular or genetic tests that might not have been done on older samples. The biopsy confirms the exact diagnosis and may identify particular genetic markers or proteins that the experimental treatment targets.^[2]

For trials testing targeted therapies—drugs designed to attack cancer cells with specific characteristics—comprehensive laboratory analysis of the biopsy tissue is essential. These tests might look for particular gene mutations, protein expressions, or chromosomal changes that make the cancer likely to respond to the treatment being studied.^[2]

Imaging for Staging and Monitoring

Clinical trials typically require baseline imaging to document the size and location of all tumors before treatment begins. This usually includes chest CT scans to evaluate lung metastases, since this is where metastatic soft tissue sarcoma most commonly appears. Depending on the trial, additional imaging such as MRI scans of the primary tumor site, PET scans for whole-body assessment, or bone scans may also be required.^[2]

These imaging tests establish a starting point against which doctors can measure whether the experimental treatment is working. During the trial, patients undergo repeat imaging at specified intervals, allowing researchers to track changes in tumor size and detect any new areas of spread. This systematic monitoring is one of the most important aspects of clinical trial participation, as it provides the data needed to evaluate treatment effectiveness.^[2]

Blood Tests and Organ Function Assessment

Blood tests are standard requirements for clinical trial enrollment because researchers need to ensure participants are healthy enough to tolerate the experimental treatment. Complete blood counts check that patients have adequate numbers of red blood cells, white blood cells, and platelets. Blood chemistry panels assess kidney and liver function, as many cancer treatments are processed through these organs.^[2]

Some trials may require additional specialized blood tests, such as measuring specific proteins or markers that relate to the cancer or treatment being studied. These baseline measurements help researchers understand the treatment’s effects on the body and identify any concerning changes that might occur during the study.^[2]

Performance Status Evaluation

Beyond specific medical tests, clinical trials evaluate a patient’s overall physical condition and ability to perform daily activities. This assessment, called performance status, helps ensure that participants are well enough to handle the demands of the experimental treatment and the trial schedule. While not a laboratory or imaging test in the traditional sense, this evaluation is a crucial diagnostic criterion for trial eligibility.

The diagnostic requirements for clinical trials are more extensive than those for standard care, but they serve important purposes. They protect patient safety by ensuring only appropriate candidates enroll, and they provide the rigorous data needed to determine whether new treatments should become standard options for future patients with metastatic sarcoma.^[4]

⚠️ Important

Patients interested in clinical trials should discuss this option with their healthcare team early in their treatment planning. The diagnostic tests required for trial enrollment may take time to schedule and complete, and some trials have limited spaces available. Early planning ensures patients don’t miss opportunities to access potentially beneficial experimental treatments.

Prognosis and Survival Rate

Prognosis

The outlook for patients with metastatic soft tissue sarcoma depends on multiple factors that doctors consider when estimating how the disease might progress. The size of the tumor plays an important role, with tumors measuring 5 centimeters or smaller generally associated with better outcomes than larger tumors. The grade of the sarcoma, which describes how abnormal the cancer cells look under a microscope and how quickly they are likely to grow, significantly affects prognosis. Low-grade sarcomas tend to be less aggressive and are less likely to spread or return after treatment compared to high-grade sarcomas.^[18]

The location and depth of the original tumor also influence outcomes. Soft tissue sarcomas that develop in the arms, legs, or on the surface of the body’s trunk typically have more favorable prognoses than those starting in other body areas. Tumors growing deep within the fascia—the connective tissue wrapping around muscles, nerves, and organs—tend to have poorer outlooks. Certain sarcoma types are inherently more aggressive, including malignant peripheral nerve sheath tumors, leiomyosarcoma, and epithelioid sarcoma.^[18]

Whether the cancer was completely removed during surgery significantly impacts prognosis. When surgeons can remove all visible tumor with clear margins (meaning no cancer cells at the edges of the removed tissue), outcomes improve substantially. Unfortunately, for metastatic disease where surgery cannot completely eliminate all cancer, the outlook becomes more challenging. The age of the patient also matters, with people under 50 generally experiencing better outcomes than older individuals.^[18]

Survival rate

Patients with metastatic soft tissue sarcoma generally face serious challenges, as this represents stage 4 disease where cancer has spread to distant parts of the body. According to medical literature, the median overall survival for patients with metastasized soft tissue sarcoma is approximately 12 months. However, this figure represents an average, and individual outcomes vary considerably based on the factors mentioned above.^[4]

More recent treatment advances have shown some improvement in survival times. Studies of systemic treatments have reported median overall survival ranging from 16 to 17 months for patients receiving modern chemotherapy regimens. It is important to understand that about 50% of patients diagnosed with localized high-grade soft tissue sarcoma eventually develop pulmonary metastases, and in approximately 70% of these cases, the lungs remain the only site of metastatic disease.^[10]

The prognosis for metastatic sarcoma remains poor overall, but individual circumstances vary widely. Some patients with limited metastatic disease that can be surgically removed may have better outcomes than those with widespread disease. The specific subtype of sarcoma, response to treatment, and overall health of the patient all contribute to survival. While these statistics can help patients and families understand the general outlook, every person’s journey with metastatic sarcoma is unique, and some individuals survive much longer than average estimates would suggest.^[4]

#1 Clinical Trials Search in Europe